

5 ©2020 EDQM, Council of Europe. All rights reserved.

Common Technical Specifications (CTS)

What are the CTS?

They establish performance evaluation and re-evaluation criteria, batch release criteria, reference methods and reference materials;

As a general rule, manufacturers of IVD are required to comply with the CTS;

Commission Decision 2002/364/EC on Common Technical Specifications for In Vitro Diagnostics

Updated by;


2009/886/EC - to reflect technical progress in the performance and analytical sensitivity of devices


2019/1244 - Requirements for HIV and HCV antigen and antibody combined tests and requirements for nucleic acid amplification techniques with respect to reference materials and qualitative HIV assays;

2020/35 - Definitions of first–line assays and confirmatory assays, requirements for devices for self-testing and requirements for HIV and HCV rapid tests, confirmatory and supplementary assays

6 ©2020 EDQM, Council of Europe. All rights reserved.







HBsAg:		re+/tot	al re+ percent	*Core Sample	
 O.10 IU/ml B-PTS007 B-PTS021 B-PTS028 	not defined core * core	43/43 64/64 71/71	100.0% 100.0% 100.0%	Sample that has to be correctly determined as reacting non-reactive for a satisfactory performance:	
B-PTS035	core <i>adw2</i> /gt A core <i>ayw3</i> /D2	80/81 77/81	98.8% 95.1%	**Non Core Sample	
B-PTS041	core <i>adw2</i> /gt A core <i>ayw3</i> /D2	76/76 76/76	100.0% 100.0%	Sample that does not require to be found reactive or non-reactive for a satisfactory performance - used for	
B-PTS048	core <i>adw2</i> /gt A core <i>adr</i> /C2	67/67 67/67	100.0% 100.0%	educative purpose in the study:	
> 0.05 IU/ml				Trend analysis performed -B-PTS Advisory Group	
B-PTS007	not defined	42/43	97.7%	M. Chudy, M.L Hecquet, D. Sondag, S.Pupella, G.Pisani, E. Regourd	
B-PTS021	non-core**	64/64	100.0%		
B-PTS028	core	70/71	98.6%	Where unsatisfactory performance has occurred –	
B-PTS035	core adw2/gt A		90.1%	cases where this could be attributed to the	
B-PTS041	core adw2/gt A	75/76	98.7%	analytical sensitivity of the assay	
B-PTS048	core <i>adw2</i> /gt A	64/67	95.5%		

HBsAg – Consideration for CTS

HBsAg assays used for screening of blood donors and for diagnosis of patients suspected of having HBV infection;

Performance requirements should correspond to the expected HBsAg Levels

Blood Donors – better analytical sensitivity needed – low HBsAg levels


Diagnosis of Patients – high analytical sensitivity not as critical? – HBsAg levels generally high;

Candotti D et. Al Transfusion Transmission of Hepatitis B Virus: still learning more about it. ISBT Science Series (2011) 6, 234–240 World Health Organisation – Performance Evaluation Acceptance Criteria for HBsAg In vitro diagnostics in the context of WHO Prequalification Jaroszewicz J et. al. Hepatitis B Surface Antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV) infection: A European perspective. J Hepatology 2010 vol 52 j 514-522

10 ©2020 EDQM, Council of Europe. All rights reserved.

edom

C



B-PTS Programme – Perspectives and Objectives

	CONCLUDED STUDIES	2017	2018	2019
	HCV/HBV/HIV NAT	97.40%	100%	100%
Continue to monitor and	Anti-HCV	94.30 %	100%	100%
mprove the programme based	Anti-HIV/p24	88.70%	100%	100%
on trends and observations;	Anti-Treponema	94 %	94 %	94 %
immunohematology –	HBsAg/anti-HBc	82,4% (HBsAg) 100% (anti-HBc)	98 % (HBsAg) 100 % (anti-HBc)	98 % (HBsAg) 100 % (anti-HBc)
IA for patient testing	ABo, Rh Grouping	96% (ABO, Rh) 94% (Ext. phenotyping) 76% (Ir. Antibodies)	97 % (ABO, Rh) 93 % (Ext. phenotyping) 75 % (Ir. antibodies)	97 % (ABO, Rh) 93 % (Ext. phenotyping) 75 % (Ir. antibodies)
Quality	Control Screening Study			
Bacteriai		- A		

MEMBERS	ORGANISATION	 Proposals for annual B-PTS programme and future studies;
M. Chudy	Paul Ehrlich Institut, Germany	Nomination of Scientific Advisors for B-PTS studies
G. Pisani	Istituto Superiore di Sanità, Italy	 Provide support for scientific, technical and logistical issues of the activity;
S. Pupella	National Blood Center, National Institute of Health, Italy	 Provide advice regarding the improvement of the studies and the activity;
D. Sondag	Croix Rouge, Belgium	 Produce additional material (e.g. guidance) in relation to the B-PTS activity, based on evidence
M. Riley	National Blood Transfusion Centre, Malta	collected during the B-PTS activity;
M. Prax	Paul Ehrlich Institut, Germany	 Provide recommendations to relevant parties on scientific/regulatory aspects based on outcomes and evidence collected during the B-PTS activity,



